- Home
- PPC vs MRNA Comparison
PPC vs MRNA Comparison
Compare PPC & MRNA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PPC
- MRNA
- Stock Information
- Founded
- PPC 1946
- MRNA 2010
- Country
- PPC United States
- MRNA United States
- Employees
- PPC N/A
- MRNA N/A
- Industry
- PPC Meat/Poultry/Fish
- MRNA Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- PPC Consumer Staples
- MRNA Health Care
- Exchange
- PPC Nasdaq
- MRNA Nasdaq
- Market Cap
- PPC 10.4B
- MRNA 9.8B
- IPO Year
- PPC 1987
- MRNA 2018
- Fundamental
- Price
- PPC $38.17
- MRNA $27.38
- Analyst Decision
- PPC Hold
- MRNA Hold
- Analyst Count
- PPC 4
- MRNA 17
- Target Price
- PPC $47.50
- MRNA $42.40
- AVG Volume (30 Days)
- PPC 1.7M
- MRNA 12.1M
- Earning Date
- PPC 10-29-2025
- MRNA 11-06-2025
- Dividend Yield
- PPC 21.78%
- MRNA N/A
- EPS Growth
- PPC 62.69
- MRNA N/A
- EPS
- PPC 5.19
- MRNA N/A
- Revenue
- PPC $18,177,417,000.00
- MRNA $3,078,000,000.00
- Revenue This Year
- PPC $3.90
- MRNA N/A
- Revenue Next Year
- PPC $0.67
- MRNA $9.75
- P/E Ratio
- PPC $7.43
- MRNA N/A
- Revenue Growth
- PPC 2.06
- MRNA N/A
- 52 Week Low
- PPC $37.43
- MRNA $23.15
- 52 Week High
- PPC $57.16
- MRNA $60.65
- Technical
- Relative Strength Index (RSI)
- PPC 25.84
- MRNA 56.40
- Support Level
- PPC $39.90
- MRNA $23.91
- Resistance Level
- PPC $41.45
- MRNA $28.99
- Average True Range (ATR)
- PPC 1.05
- MRNA 1.22
- MACD
- PPC -0.11
- MRNA 0.38
- Stochastic Oscillator
- PPC 14.29
- MRNA 67.03
About PPC Pilgrim's Pride Corporation
Pilgrim's Pride is the second-largest poultry producer in the US (59% of 2024 sales), the UK (29% including other European sales), and Mexico (12%). Its UK and European arm also includes pork operations from the 2019 acquisition of Tulip. Pilgrim's sells to chain restaurants, food processors, food distributors, and retail chains. Most of its US and Mexican sales come from fresh chicken, while prepared chicken and pork constitute most of its UK and European sales. JBS owns more than 80% of Pilgrim's Pride's outstanding shares, though it failed to acquire the remaining stake in 2021 after a special board committee deemed that JBS' offer undervalued Pilgrim's Pride.
About MRNA Moderna Inc.
Moderna is a commercial-stage biotech that was founded in 2010 and had its initial public offering in December 2018. The firm's mRNA technology was rapidly validated with its covid vaccine, which was authorized in the United States in December 2020. Moderna had 35 mRNA development candidates in clinical studies as of August 2025. Programs span a wide range of therapeutic areas, including infectious disease, oncology, cardiovascular disease, and rare genetic diseases.